KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 February 2024 - 10:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted four newly-hired employees inducement options to purchase
an aggregate of 42,000 shares of KalVista common stock on February
1, 2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $15.74 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista is developing sebetralstat as an
oral on-demand therapy for HAE and anticipates providing data from
the phase 3 KONFIDENT clinical trial in early 2024. In addition,
KalVista’s oral Factor XIIa inhibitor program represents a new
generation of therapies that may further improve the treatment for
people living with HAE and other diseases.
For more information about KalVista, please visit
www.kalvista.com
For more information on the sebetralstat HAE on-demand Phase 3
KONFIDENT study, please visit www.konfidentstudy.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240202998919/en/
KalVista Pharmaceuticals, Inc.
Jarrod Aldom Vice President, Corporate Communications (201)
705-0254 jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2024 to May 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From May 2023 to May 2024